Physician profile

David M Keelen

Pain Medicine · Frisco, TX

NPI 1790088508

$34,835.80

in general payments reported to CMS, 2019-2025

43 companies · $23K in 2025

The $23K reported for 2025 was more than what 97% of Pain Medicine providers received nationally (typical 2025 total: $515).

See the full distribution for Pain Medicine

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$16,750.00
Travel and Lodging$4,949.34
Food and Beverage$2,537.39

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Saluda Medical Americas, INC. $23,059.69 2020-2025 Evoke
Flowonix Medical Incorporated $6,428.55 2019
Collegium Pharmaceutical, INC. $833.72 2019-2024 Xtampza
Forte Bio-Pharma LLC $521.14 2019-2024 Prolate, Nalocet
Medtronic, INC. $440.94 2021-2025 Inceptiv, Accurian
Abbvie INC. $324.48 2021-2025
Medtronic USA, INC. $324.42 2019-2020
Abbott Laboratories $269.22 2019-2025 Proclaim, Penta
Tersera Therapeutics LLC $266.61 2019-2023 Prialt
Biohaven Pharmaceutical Holding Company LTD. $208.60 2022
Amgen INC. $191.29 2019-2022
Scilex Pharmaceuticals INC. $188.10 2019-2025 Ztlido
Pfizer INC. $180.48 2023-2025
Nevro Corp. $174.96 2019-2022
Arbor Pharmaceuticals, INC. $141.82 2019-2022
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Horizon Therapeutics Plc $138.70 2020-2022
Boston Scientific Corporation $122.02 2019-2023 Wavewriter Alpha Prime 16
Almatica Pharma LLC $104.01 2021-2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $91.57 2021-2023 Relistor
Teva Pharmaceuticals USA, INC. $84.17 2019-2022
Novartis Pharmaceuticals Corporation $63.57 2020-2021
Biohaven Pharmaceuticals, INC. $58.72 2021
Virtus Pharmaceuticals LLC $56.78 2021
Biodelivery Sciences International, INC. $53.85 2019-2020
Currax Pharmaceuticals LLC $49.91 2019-2021
Assertio Therapeutics, INC. $43.54 2019
Avanos Medical $42.26 2019-2020
Valinor Pharma, LLC $38.75 2023 Movantik
Vertiflex, INC. $32.15 2019
Vertex Pharmaceuticals Incorporated $30.97 2025
Lilly USA, LLC $28.85 2022
Kowa Pharmaceuticals America, INC. $28.35 2022
Allergan, INC. $26.57 2020
Mml US, INC. $26.05 2025 Reactiv8
Nuvasive, INC. $24.07 2019
Eisai INC. $20.07 2021
Titan Pharmaceuticals, INC. $18.30 2020
Globus Medical, INC. $18.24 2025 Senza
Spr Therapeutics, INC $17.40 2023 Sprint Pns System
Si-Bone, INC. $17.02 2019
Vertical Pharmaceuticals, LLC $16.28 2019
Mdd US Operations, LLC $15.55 2019
Vertos Medical, INC. $14.06 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$163.13 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David M Keelen

$34,835.80

in general payments reported 2019-2025

Years
2019-2025
Top company
Saluda Medical Americas, INC.
Context
The $23K reported for 2025 was more than what 97% of Pain Medicine providers received nationally (typical 2025 total: $515).

https://glasscript.com/doctor/80752/david-m-keelen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.